The Gut's Secret Code: Bowel Microbiota as a Biomarker for Adaptation

Area of Science:

• Gastroenterology
• Microbiology
• Surgical Science

Background:

• Chronic intestinal failure (CIF), often due to short bowel syndrome (SBS) from extensive resection, causes malabsorption and parenteral nutrition (PN) dependence.
• SBS significantly alters the gut microbiota, with potential links to adverse outcomes like liver disease and impaired growth, but also beneficial effects like energy salvage.
• Intestinal adaptation, crucial for SBS management, involves increasing absorptive capacity through distinct phases.

Purpose of the Study:

• To review the role of the gut microbiota in intestinal adaptation in SBS.
• To explore the potential of gut microbiota as a biomarker and therapeutic target for SBS.
• To summarize current and emerging strategies for managing SBS.

Main Methods:

• Literature review focusing on gut microbiota alterations in SBS.
• Analysis of the mechanisms of intestinal adaptation.
• Evaluation of therapeutic interventions for SBS.

Main Results:

• Gut microbiota composition changes significantly after small bowel resection in SBS patients.
• Dysbiosis in SBS is associated with negative health outcomes but may also offer benefits.
• Gut microbiota composition is a promising non-invasive biomarker for predicting adaptation success.

Conclusions:

• GLP-1 and GLP-2 analogues show potential for enhancing intestinal adaptation and reducing PN dependence.
• Surgical rehabilitation and intestinal transplantation are key management strategies, with transplantation reserved for severe cases.
• Further research is essential to fully understand and leverage the gut microbiota's role in SBS management.